BUSINESS COMBINATION (Tables)

9 Months Ended

Sep. 30, 2013

Costs incurred through September 30, 2013, include:

Category
Legal fees	$	1,226,535
Accounting fees		121,748
Consulting fees		119,194
Monitoring and advisory fees		390,000
Transaction bonuses		4,801,364
Other		428,992
Total transaction costs	$	7,087,833

Business Combination Purchase Price Allocation

The following presents the preliminary allocation of the purchase consideration to the assets acquired and liabilities assumed on June 19, 2013:

Fair value of BioSante shares outstanding	$	29,795,133
Estimated fair value of vested BioSante stock options		-
Total purchase consideration	$	29,795,133

Assets acquired
Cash and cash equivalents	$	18,197,442
Restricted cash		2,260,100
Teva license intangible asset		10,900,000
Other tangible assets		79,261
Deferred tax assets, net		-
Goodwill		1,838,309
Total assets		33,275,112

Liabilities assumed
Accrued severance		2,964,962
Other liabilities		515,017
Total liabilities		3,479,979
Total net assets acquired	$	29,795,133

Business Acquisition, Pro Forma Information

The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the Merger had occurred as of January 1, 2012 or that may be obtained in the future.

	Three months ended September 30,				Nine months ended September 30,
	2013		2012		2013		2012
Net revenues	$	7,836,222	$	5,146,407	$	19,694,710	$	15,382,782
Net income/(loss)	$	1,691,720	$	(6,246,057)	$	(3,178,713)	$	(23,066,678)